根据Exact Sciences的建模数据预测，在过去10年中，已有超过1600万人通过Cologuard测试完成了筛查。这也推动了美国50-75岁群体的结肠癌筛查率，从2015年的63%上升到2021年的72%。 这一极具社会价值的成就，为Exact ...

U.S. households will be able to order as many as four nasal swab tests at COVIDTests.gov when the federal program reopens.

In a separate study published in March by the same journal, an updated version of the Cologuard stool test, which also looks ...

In July, the Summer Law and Trial Institute (SLTI) welcomed 24 high school students from across the state of Ohio both to Athens and to the practice of law. OHIO's faculty and staff, across various ...

Imagine watching your dog waddle into the room and noticing that he is walking on the top of his back paw. While you may ...

Health officials on Thursday said they don’t know how a Missouri person caught bird flu but believe it may be a rare instance of a “one-off” standalone ...

Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue-based ...

A rival CEO's confrontational social media post underscored the high stakes in the race to develop and deploy cancer ...

A team from Kumamoto University has uncovered a new mechanism that could revolutionize infertility care by promoting embryo ...

A victory for the Federal Trade Commission, set to conclude Tuesday, could pave the way for an Amazon buying spree. The deal further expands Carlyle's push into asset-based finance.

周一，Canaccord Genuity重申了Exact Sciences Corporation (NASDAQ:EXAS)的买入评级，并维持75美元的目标价。这一背书是在该公司在2024年欧洲医学肿瘤学会（ESMO）大会上宣布其基于血液的结直肠癌（CRC）筛查测试的新性能数据之后做出的。 这项旨在提高新型生物标志物特异性的测试显示，对CRC的检测敏感性为88%，对进展性腺瘤（AA）的敏感性为3 ...